Neuroendocrine response to antipsychotics: Effects of drug type and gender

Biological Psychiatry

Volumn 45, Issue 1, 1999, Pages 89-97

  Gründer, Gerhard ^a   Wetzel, Hermann ^a   Schlösser, Ralf ^a   Anghelescu, Ion ^a   Hillert, Andreas ^a   Lange, Knut ^a   Hiemke, Christoph ^a   Benkert, Otto ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Amisulpride; Flupenthixol; Growth hormone; Prolactin; Thyrotropin; Thyrotropin releasing hormone

Indexed keywords

AMISULPRIDE; CHLORAL HYDRATE; DOPAMINE 1 RECEPTOR; FLUPENTIXOL; GROWTH HORMONE; HISTAMINE H1 RECEPTOR; NEUROLEPTIC AGENT; PROLACTIN; SEROTONIN RECEPTOR; THYROTROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GENDER; HORMONE RELEASE; HUMAN; MALE; MULTICENTER STUDY; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; FLUPENTHIXOL; HUMAN GROWTH HORMONE; HUMANS; MALE; NEUROSECRETORY SYSTEMS; PROLACTIN; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEX FACTORS; SULPIRIDE; THYROTROPIN;

EID: 0345059247     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(98)00125-5     Document Type: Article

References (51)

1. Anderson M.S., Bowers C.Y., Kastin A.J., Schalch D.S., Schally A.V., Snyder P.J., et al. Synthetic thyrotropin-releasing hormone A potent stimulator of thyrotropin secretion in man . N Engl J Med. 285:1971;1279-1283.
2. Andreasen N.C. The Scale for the Assessment of Negative Symptoms. 1983;The University of Iowa, Iowa City, IA.
3. Andreasen N.C. The Scale for the Assessment of Positive Symptoms. 1984;The University of Iowa, Iowa City, IA.
4. Angermeyer M.C., Kuhn L., Goldstein J.M. Gender and the course of schizophrenia. Differences in treated outcomes. Schizophr Bull. 16:1990;293-307.
5. Asa S.L., Penz G., Kovacs K., Ezrin C. Prolactin cells in the human pituitary A quantitative immunocytochemical analysis of human pituitaries taken at autopsy . Arch Pathol Lab Med. 106:1982;360-363.
6. Bansal S.A., Lee L.A., Woolf P.D. Dopaminergic regulation of growth hormone (GH) secretion in normal men Correlation of L-dopa and dopamine levels with the GH response . J Clin Endocrinol Metab. 53:1981;301-306.
7. Belchetz P.E., Gredley G., Bird D., Himsworth R.L. Regulation of thyrotropin secretion by negative feedback of triiodothyronine on the hypothalamus. J Endocrinol. 76:1977;439-448.
8. Besses G.S., Burrow G.N., Spaulding S.W., Donabedian R.K. Dopamine infusion acutely inhibits the TSH and prolactin response to TRH. J Clin Endocrinol Metab. 41:1975;983-987.
9. Bischof S., Christen P., Vassout A. Blockade of hippocampal dopamine receptors A tool for antipsychotics with low extrapyramidal side effects . Prog Neuropsychopharmacol Biol Psychiatry. 12:1988;445-467.
10. Boyer P., Lecrubier Y., Puech A.J., Dewailly J., Aubin F. Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry. 166:1995;68-72.
11. De Marinis L., Mancini A., Calabro F., Massari M., Torlontano M., Barbarino A. Differential effects of a dopaminergic drug (piribedil) on pituitary hormone release in normal men and women. Acta Endocrinol. 104:1983;385-389.
12. Dufour A., Desanti C. Pharmacocinétique et métabolisme de l'amisulpride. Ann Psychiatr. 3:1988;298-305.
13. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry. 49:1992;538-544.
14. Gruen P.H., Sachar E.J., Langer G., Altman N., Leifer M., Frantz A., et al. Prolactin responses to neuroleptics in normal and schizophrenic subjects. Arch Gen Psychiatry. 35:1978;108-116.
15. Gründer G., Wetzel H., Hillert A., Jochum E., Hiemke C., Benkert O. The neuroendocrinological profile of roxindole, a dopamine autoreceptor agonist, in schizophrenic patients. Psychopharmacology (Berl). 117:1995;472-478.
16. Gudelsky G.A., Nash J.F., Berry S.A., Meltzer H.Y. Basic biology of clozapine Electrophysiological and neuroendocrinological studies . Psychopharmacology (Berl). 99:1989;S13-S17.
17. Härnryd C., Bjerkenstedt L., Gullberg B., Oxenstierna G., Sedvall G., Wiesel F.A. Time course for effects of sulpiride and chlorpromazine on monoamine metabolite and prolactin levels in cerebrospinal fluid from schizophrenic patients. Acta Psychiatr Scand. 69:(suppl 311):1984;75-92.
18. Hinkle P.M., Perrone M.H., Schonbrunn A. Mechanism of thyroid hormone inhibition of thyrotropin-releasing hormone action. Endocrinology. 108:1981;199-205.
19. Ishibashi M., Yamaji T. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture. J Clin Invest. 73:1984;66-78.
20. Kakigi T., Maeda K., Tanimoto K., Kaneda H., Shintani T. Effect of substituted benzamides on prolactin secretion in the rat. Biol Psychiatry. 31:1992;827-831.
21. Lal S., Guyda H., Bikadoroff S. Effect of methysergide and pimozide on apomorphine-induced growth hormone secretion in man. J Clin Endocrinol Metab. 44:1977;766-770.
22. Lawton N.F., Evans A.J., Weller R.O. Dopaminergic inhibition of growth hormone and prolactin release during continuous in vitro perfusion of normal and adenomatous human pituitary. J Neurol Sci. 49:1981;229-239.
23. Leong D.A., Frawley L.S., Neill J.D. Neuroendocrine control of prolactin secretion. Annu Rev Physiol. 45:1983;109-127.
24. 2 receptors . Psychopharmacology (Berl). 112:1993;40-54.
25. Linkowski P., Hubain P., von Frenckell R., Mendlewicz J. Haloperidol plasma levels and clinical response in paranoid schizophrenics. Eur Arch Psychiatr Neurol Sci. 234:1984;231-236.
26. Maeda K., Kato Y., Ohgo S., Chihara K., Yoshimoto Y., Yamaguchi N., et al. Growth hormone and prolactin release after injection of thyrotropin-releasing hormone in patients with depression. J Clin Endocrinol Metab. 40:1975;501-503.
27. 2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology (Berl). 124:1996;154-158.
28. Meltzer H.Y., Fang V.S. The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry. 33:1976;279-286.
29. Meltzer H.Y., Busch D.A., Fang V.S. Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response. Psychiatry Res. 9:1983;271-283.
30. Noel G.L., Dimond R.C., Wartofsky L., Earll J.M., Frantz A.G. Studies of prolactin and TSH secretion by continuous infusion of small amounts of thyrotropin-releasing hormone (TRH). J Clin Endocrinol Metab. 39:1974;6-17.
31. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol Rep. 10:1962;799-812.
32. 3 dopamine receptor antagonist activity and limbic selectivity . J Pharmacol Exp Ther. 280:1997;73-82.
33. Pichot P, Boyer P (1989): A controlled double-blind multicentre trial of high dose amisulpride versus haloperidol in acute psychotic states. In: Borenstein P, Boyer P, Braconnier A, Carnoi P, Clerc G, Costa e Silva J-A et al., editors. Amisulpride. Paris: Expansion Scientifique Francaise, pp 83-92.
34. Puech A.J., Rioux P., Poncelet M., Brochet D., Chermat R., Simon P. Pharmacological properties of new antipsychotic agents Use of animal models . Neuropharmacology. 20:1981;1279-1284.
35. Rao V.A.R., Bishop M., Coppen A. Clinical state, plasma levels of haloperidol and prolactin A correlation study in chronic schizophrenia . Br J Psychiatry. 137:1980;518-521.
36. Raymond V., Beaulieu M., Labrie F., Boissier J. Potent antidopaminergic activity of estradiol at the pituitary level on prolactin release. Science. 200:1978;1173-1175.
37. Scanlon M.F., Lewis M., Weightman D.R., Chan V., Hall R. The neuroregulation of human thyrotropin secretion. Front Neuroendocrinol. 6:1980;333-380.
38. 3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther. 280:1997;83-97.
39. Seeman M.V. Gender differences in schizophrenia. Can J Psychiatry. 27:1982;108-111.
40. Stone R.T., Maurer R.A., Gorski J. Effect of estradiol-17b on preprolactin messenger ribonucleic acid activity in the rat pituitary gland. Biochemistry. 16:1977;4915-4921.
41. Swigar M.E., Jatlow P.I., Goicoechea N., Opsahl C., Bowers M.B. Ratio of serum prolactin to haloperidol and early clinical outcome in acute psychosis. Am J Psychiatry. 141:1984;1281-1283.
42. Szymanski S., Lieberman J.A., Alvir J.M., Mayerhoff D., Loebel A., Geisler S., et al. Gender differences in onset of illness, treatment response, course, and biological indexes in first-episode schizophrenic patients. Am J Psychiatry. 152:1995;698-703.
43. Tuomisto J., Männistö P. Neurotransmitter regulation of anterior pituitary hormones. Pharmacol Rev. 37:1985;249-332.
44. van de Kar L.D. Neuroendocrine pharmacology of serotonergic (5-HT) neurons. Annu Rev Pharmacol Toxicol. 31:1991;289-320.
45. van Putten T., Marder S.R., Mintz J. Serum prolactin as a correlate of clinical response to haloperidol. J Clin Psychopharmacol. 11:1991;357-361.
46. von Bahr C., Wiesel F.-A., Movin G., Eneroth P., Jansson P., Nilsson L., et al. Neuroendocrine responses to single oral doses of remoxipride and sulpiride in healthy female and male volunteers. Psychopharmacology (Berl). 103:1991;443-448.
47. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 44:1987;660-669.
48. 2-like receptors by amisulpride: Effects on hormone secretion in healthy volunteers. J Psychiatr Res. 28:1994;461-473.
49. Wetzel H, Gründer G, Philipp M, Hillert A, Gattaz WF, Sauer H, Adler G, et al (1998): High-dose amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology - A double-blind controlled study. Psychopharmacology (Berl) 137:223-232.
50. Widloecher D., Allilaire J.F., Guerard des Lauriers A., Lecrubier Y. L'amisulpride, neuroleptique et antidéficitaire. Encephale. 16:1990;159-163.
51. Wiesel F.A., Nordström A.L., Farde L., Eriksson B. An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology (Berl). 114:1994;31-38.